Xenon MRI and Progressive ILD

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

XENON ILD: 129Xe MRI to Evaluate aNtifibrotic respOnse and progressioN in ILD

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05241275
• Other study ID #: Pro00109322
• Status: Recruiting
• Phase: Phase 2
• Start date: July 19, 2022
• Est. completion date: June 1, 2026

Study information

• Verified date: January 2024
• Source: Duke University
• Contact: Claudia Salazar
• Phone: 9196602026
• Email: claudia.salazar[@]duke.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung disease (ILD). Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyperpolarized 129Xe. The subjects will have this initial study prior to initiation of anti-fibrotic therapies and repeat MRI studies at 3, 6 and 12 months following the initiation of therapy. If subjects do not decide to initiate anti-fibrotic therapy per discussion with their physician, then the 3, 6 and 12 months repeat studies will initiate based on time after enrollment.

Description:

The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-IPF PF-ILD. Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyperpolarized 129Xe. The subjects will have this initial study prior to initiation of anti-fibrotic therapies and repeat MRI studies at 3, 6 and 12 months following the initiation of therapy. If subjects do not decide to initiate anti-fibrotic therapy per discussion with their physician, then the 3, 6 and 12 months repeat studies will initiate based on time after enrollment. We plan to consent 75 subjects with PF-ILD who are candidates for anti-fibrotic therapy to slow ILD progression. We will ensure that the study will include at least 38 subjects who start anti-fibrotic therapy after baseline first MRI scan and continue the therapy until his/her 3 month repeat MRI scan. This will be obtained by a pre-specified increase in the number of subjects until the 38 subject criteria is completed. Subject will not be excluded from the study due to stopping anti-fibrotic therapy for any reason during the study.

Additional studies including pulmonary function studies, plasma and serum for biomarkers, whole blood for DNA (baseline visit only), whole blood for RNA, exhaled breath for biomarkers, 6 minute walk distance and a HRCT (only at the screening visit, 6 month visit, and 12 month visit) will be performed to determine how 129Xe MRI performs relative to standard of care evaluations for PF-ILD patients. Finally, following the study visits the research team will prospectively follow the patients' clinical course through periodic reviews of the medical record.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: June 1, 2026
• Est. primary completion date: June 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• We will include all patients who are over 18 years of age with a physician-diagnosed ILD of one of the below subtypes based on multidisciplinary consensus

1. Chronic hypersensitivity pneumonitis

2. Autoimmune interstitial lung disease (including rheumatoid arthritis-ILD, mixed connective tissue disorder related ILD, myositis related ILD, scleroderma related ILD, and idiopathic pneumonia with autoimmune features)

3. Idiopathic NSIP

4. Unclassifiable idiopathic interstitial pneumonia

• Fibrotic lung disease affecting more than 10% of lung volume on high-resolution CT, per Duke radiology review

• Evidence of any of the following criteria for progression of ILD within the 24 months before screening:

1. Relative decline in FVC % predicted of at least 10%

2. Relative decline in FVC % predicted = 5% - < 10 combined with either increasing extent of fibrotic changes on HRCT or worsening of respiratory symptoms

3. Worsening respiratory symptoms and increased extent of fibrosis on HRCT

• Willing and able to give informed consent and adhere to visit/protocol schedules

• Immunosuppressive medication, including azathioprine, cyclosporine, mycophenolate mofetil, rituximab, cyclophosphamide, or oral glucocorticoids are permitted at the discretion of the treating physician

Exclusion Criteria:

• Subject is less than 18 years of age

• Prior treatment with nintedanib or pirfenidone

• Subject is pregnant or lactating

• Prior investigational drug use within 28 days

• MRI is contraindicated based on responses to MRI screening questionnaire

• Respiratory illness of a bacterial or viral etiology within 30 days of MRI

• Acute exacerbation within 30 days of MRI, defined by acute increases in oxygen requirement, bilateral alveolar filling opacities on imaging, and the need for antibiotics and/or systemic steroids

• Subject does not fit into 129Xe vest coil used for MRI

• Subject with ventricular cardiac arrhythmia in the past 30 days.

• Subject has history of cardiac arrest within the last year

• Subject deemed unlikely to be able to comply with instructions during imaging

• Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis

Locations

Country	Name	City	State
United States	Duke University	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	Boehringer Ingelheim

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in 129Xe MRI barrier uptake 3 months after anti-fibrotic initiation	The outcome will assess changes in 129Xe MRI barrier uptake 3 months after nintedanib initiation.	Baseline, 3 months
Secondary	Change in 129Xe MRI barrier uptake 6 months after anti-fibrotic initiation	The outcome will assess changes in 129Xe MRI barrier uptake 6 months after nintedanib initiation.	Baseline and 6 months
Secondary	Change in 129Xe MRI RBC to barrier ratio 3 months after anti-fibrotic initiation	RBC to barrier ratio is a ratio of the RBC transfer and barrier values and is reported as a single value	Baseline and 3 months
Secondary	Change in 129Xe MRI RBC to barrier ratio 6 months after anti-fibrotic initiation	RBC to barrier ratio is a ratio of the RBC transfer and barrier values and is reported as a single value	Baseline and 6 months
Secondary	Time to disease progression (occurrence of a = 10% drop in percent predicted FVC, all cause death, or lung transplant) in individuals with elevated barrier uptake at baseline greater than 2 standard deviations of a healthy reference cohort	Time to disease progression will be recorded in months	Up to 12 months
Secondary	Time to disease progression (occurrence of a = 10% drop in percent predicted FVC, all cause death, or lung transplant) in individuals with decreased RBC transfer at baseline, lower than 2 standard deviations of a healthy reference cohort	Time to disease progression will be recorded in months	Up to 12 months
Secondary	Time to disease progression (occurrence of a = 10% drop in percent predicted FVC, all cause death, or lung transplant) in individuals with a reduced RBC to barrier ratio, greater than 2 standard deviations of a healthy reference cohort	RBC to barrier ratio is a ratio of the RBC transfer and barrier values and is reported as a single value. Time to disease progression will be recorded in months	Up to 12 months
Secondary	Time to acute exacerbation or respiratory hospitalization in individuals with elevated barrier uptake at baseline greater than 2 standard deviations of a healthy reference cohort	Time to acute exacerbation or respiratory hospitalization will be an aggregate value and will be recorded in months	Up to 12 months
Secondary	Time to acute exacerbation or respiratory hospitalization in individuals with decreased RBC transfer at baseline, lower than 2 standard deviations of a healthy reference cohort	Time to acute exacerbation or respiratory hospitalization will be an aggregate value and will be recorded in months	Up to 12 months